Drugs / SARS-CoV-2 Sclamp vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04495933 | Jul 2020 → Apr 2024 | COVID-19 | The University of Queensland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 Sclamp vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04495933 ↗ |
| Known as | sclamp vaccine | “Participants were randomly assigned to one of five treatment groups and received two doses via intramuscular injection 28 days apart of either placebo, sclamp vaccine at 5 μg,...” PMID 33887208 ↗ Apr 2021 |
| Route | Intramuscular | “administered as an intramuscular injection” NCT04495933 ↗ |